Worldwide exclusive rights for AAV products

Extensive licenses for AAV research antibodies and ELISA test systems strengthen PROGEN´s position in the gene therapy market.

The licenses for AAV antibodies and AAV test systems from the DKFZ include several antibodies and ELISAs. With this agreement PROGEN acquired the right for the exclusive usage of the AAV ELISA technology and AAV antibodies for the development, manufacturing and sales of AAV products. 

Read more: Press release